Nektar Therapeutics (NKTR) – Investment Analysts’ Recent Ratings Changes

Nektar Therapeutics (NASDAQ: NKTR) has recently received a number of price target changes and ratings updates:

• 9/25/2026 – Nektar Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $178.00 price target on the stock.
• 9/23/2026 – Nektar Therapeutics had its price target lowered by Wedbush from $80.00 to $50.00. They now have a “neutral” rating on the stock.
• 9/16/2026 – Nektar Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $178.00 price target on the stock.
• 9/9/2026 – Nektar Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $178.00 price target on the stock.
• 8/28/2026 – Nektar Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 8/24/2026 – Nektar Therapeutics was upgraded by TD Cowen to “strong-buy”.
• 8/21/2026 – Nektar Therapeutics is now covered by JPMorgan Chase & Co.. They set a “neutral” rating and a $65.00 price target on the stock.

Insider Activity at Nektar Therapeutics

In related news, CEO Howard Robin sold 418 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $71.98, for a total transaction of $30,087.64. Following the transaction, the chief executive officer owned 54,627 shares in the company, valued at $3,932,051.46. The trade was a 0.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jonathan Zalevsky sold 5,681 shares of the business’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $70.00, for a total value of $397,670.00. Following the completion of the transaction, the insider owned 9,756 shares of the company’s stock, valued at $682,920. This represents a 36.80% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 6,285 shares of company stock worth $441,146 over the last three months. Insiders own 2.50% of the company’s stock.

Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing medicines that harness the body’s immune system to treat cancer and autoimmune and inflammatory diseases. The company’s research is centered on cytokine biology, immune-cell regulation and its proprietary polymer-conjugation technologies, which are designed to modify therapeutic compounds and potentially improve their duration, delivery or tolerability.

Nektar’s pipeline has included investigational therapies such as rezpegaldesleukin, an immune-modulating treatment being studied for autoimmune and inflammatory conditions.